Long-term Safety Rollover Study of Luspatercept in MDS, Beta-thalassemia, and MPN-Associated Myelofibrosis

Phase 3, open-label, single-arm trial of luspatercept in myelodysplastic syndrome (MDS), beta thalassemia and myelofibrosis (MF), sponsored by Celgene Corporation. Primary endpoints: Adverse Events at 42 days, Number of participants progressing to high/very high risk MDS or AML at 5 years and 3 more. Started Aug 2019; status: recruiting.